{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T10:08:00Z","timestamp":1793959680058,"version":"4.8.0"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,2,21]],"date-time":"2023-02-21T00:00:00Z","timestamp":1676937600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,2,21]],"date-time":"2023-02-21T00:00:00Z","timestamp":1676937600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100010877","name":"Science, Technology and Innovation Commission of Shenzhen Municipality","doi-asserted-by":"publisher","award":["JCYJ20200109141229255"],"award-info":[{"award-number":["JCYJ20200109141229255"]}],"id":[{"id":"10.13039\/501100010877","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Castration-resistant prostate cancer often metastasizes to the bone, and such bone metastases eventually become resistant to available therapies, leading to the death of patients. Enriched in the bone, TGF-\u03b2 plays a pivotal role in bone metastasis development. However, directly targeting TGF-\u03b2 or its receptors has been challenging for the treatment of bone metastasis. We previously found that TGF-\u03b2 induces and then depends on the acetylation of transcription factor KLF5 at K369 to regulate multiple biological processes, including the induction of EMT, cellular invasiveness, and bone metastasis. Acetylated KLF5 (Ac-KLF5) and its downstream effectors are thus potential therapeutic targets for treating TGF-\u03b2-induced bone metastasis in prostate cancer.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A spheroid invasion assay was applied to prostate cancer cells expressing KLF5<jats:sup>K369Q<\/jats:sup>, which mimics Ac-KLF5, to screen 1987 FDA-approved drugs for invasion suppression. Luciferase- and KLF5<jats:sup>K369Q<\/jats:sup>-expressing cells were injected into nude mice via the tail artery to model bone metastasis. Bioluminescence imaging, micro-CT), and histological analyses were applied to monitor and evaluate bone metastases. RNA-sequencing, bioinformatic, and biochemical analyses were used to understand nitazoxanide (NTZ)-regulated genes, signaling pathways, and the underlying mechanisms. The binding of NTZ to KLF5 proteins was evaluated using fluorescence titration, high-performance liquid chromatography (HPLC), and circular dichroism (CD) analysis.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>NTZ, an anthelmintic agent, was identified as a potent invasion inhibitor in the screening and validation assays. In KLF5<jats:sup>K369Q<\/jats:sup>-induced bone metastasis, NTZ exerted a potent inhibitory effect in preventive and therapeutic modes. NTZ also inhibited osteoclast differentiation, a cellular process responsible for bone metastasis induced by KLF5<jats:sup>K369Q<\/jats:sup>. NTZ attenuated the function of KLF5<jats:sup>K369Q<\/jats:sup> in 127 genes\u2019 upregulation and 114 genes\u2019 downregulation. Some genes\u2019 expression changes were significantly associated with worse overall survival in patients with prostate cancer. One such change was the upregulation of <jats:italic>MYBL2<\/jats:italic>, which functionally promotes bone metastasis in prostate cancer. Additional analyses demonstrated that NTZ bound to the KLF5 protein, KLF5<jats:sup>K369Q<\/jats:sup> bound to the promoter of <jats:italic>MYBL2<\/jats:italic> to activate its transcription, and NTZ attenuated the binding of KLF5<jats:sup>K369Q<\/jats:sup> to the <jats:italic>MYBL2<\/jats:italic> promoter.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>NTZ is a potential therapeutic agent for bone metastasis induced by the TGF-\u03b2\/Ac-KLF5 signaling axis in prostate cancer and likely other cancers.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12916-023-02763-4","type":"journal-article","created":{"date-parts":[[2023,2,21]],"date-time":"2023-02-21T14:05:29Z","timestamp":1676988329000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Nitazoxanide inhibits acetylated KLF5-induced bone metastasis by modulating KLF5 function in prostate cancer"],"prefix":"10.1186","volume":"21","author":[{"given":"Qingqing","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingcheng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duo","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing-Biao","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xing","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiqian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baotong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-Tang","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,2,21]]},"reference":[{"issue":"1","key":"2763_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21654","volume":"71","author":"RL Siegel","year":"2021","unstructured":"Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021. CA Cancer J Clin. 2021;71(1):7\u201333.","journal-title":"CA Cancer J Clin"},{"key":"2763_CR2","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/978-3-030-32656-2_9","volume":"1210","author":"A DiNatale","year":"2019","unstructured":"DiNatale A, Fatatis A. The bone microenvironment in prostate cancer metastasis. Adv Exp Med Biol. 2019;1210:171\u201384.","journal-title":"Adv Exp Med Biol"},{"issue":"11","key":"2763_CR3","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1111\/j.1742-1241.2011.02799.x","volume":"65","author":"M Kirby","year":"2011","unstructured":"Kirby M, Hirst C, Crawford ED. Characterising the castration-resistant prostate cancer population: a systematic review. Int J Clin Pract. 2011;65(11):1180\u201392.","journal-title":"Int J Clin Pract"},{"issue":"2","key":"2763_CR4","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.eururo.2014.07.020","volume":"68","author":"G Gandaglia","year":"2015","unstructured":"Gandaglia G, Karakiewicz PI, Briganti A, Passoni NM, Schiffmann J, Trudeau V, et al. Impact of the site of metastases on survival in patients with metastatic prostate cancer. Eur Urol. 2015;68(2):325\u201334.","journal-title":"Eur Urol"},{"issue":"5","key":"2763_CR5","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1053\/hp.2000.6698","volume":"31","author":"L Bubendorf","year":"2000","unstructured":"Bubendorf L, Schopfer A, Wagner U, Sauter G, Moch H, Willi N, et al. Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. Hum Pathol. 2000;31(5):578\u201383.","journal-title":"Hum Pathol"},{"issue":"1","key":"2763_CR6","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1001\/jama.2016.19425","volume":"317","author":"AL Himelstein","year":"2017","unstructured":"Himelstein AL, Foster JC, Khatcheressian JL, Roberts JD, Seisler DK, Novotny PJ, et al. Effect of longer-interval vs standard dosing of zoledronic acid on skeletal events in patients with bone metastases: a randomized clinical trial. JAMA. 2017;317(1):48\u201358.","journal-title":"JAMA"},{"issue":"30","key":"2763_CR7","doi-asserted-by":"publisher","first-page":"3800","DOI":"10.1200\/JCO.2012.44.6716","volume":"31","author":"MR Smith","year":"2013","unstructured":"Smith MR, Saad F, Oudard S, Shore N, Fizazi K, Sieber P, et al. Denosumab and bone metastasis-free survival in men with nonmetastatic castration-resistant prostate cancer: exploratory analyses by baseline prostate-specific antigen doubling time. J Clin Oncol. 2013;31(30):3800\u20136.","journal-title":"J Clin Oncol"},{"issue":"2","key":"2763_CR8","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.cell.2008.07.001","volume":"134","author":"J Massague","year":"2008","unstructured":"Massague J. TGFbeta in cancer. Cell. 2008;134(2):215\u201330.","journal-title":"Cell."},{"key":"2763_CR9","doi-asserted-by":"crossref","unstructured":"Hao Y, Baker D, Ten Dijke P. TGF-\u03b2-mediated epithelial-mesenchymal transition and cancer metastasis. Int J Mol Sci. 2019;20(11):2767.","DOI":"10.3390\/ijms20112767"},{"issue":"3","key":"2763_CR10","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1038\/nrm3758","volume":"15","author":"S Lamouille","year":"2014","unstructured":"Lamouille S, Xu J, Derynck R. Molecular mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell Biol. 2014;15(3):178\u201396.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"4","key":"2763_CR11","first-page":"318","volume":"9","author":"B Thompson-Elliott","year":"2021","unstructured":"Thompson-Elliott B, Johnson R, Khan SA. Alterations in TGF\u03b2 signaling during prostate cancer progression. Am J Clin Exp Urol. 2021;9(4):318\u201328.","journal-title":"Am J Clin Exp Urol"},{"issue":"10","key":"2763_CR12","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1038\/nrd3810","volume":"11","author":"RJ Akhurst","year":"2012","unstructured":"Akhurst RJ, Hata A. Targeting the TGFbeta signalling pathway in disease. Nat Rev Drug Discov. 2012;11(10):790\u2013811.","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"2763_CR13","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.trecan.2016.11.008","volume":"3","author":"S Colak","year":"2017","unstructured":"Colak S, Ten Dijke P. Targeting TGF-\u03b2 signaling in cancer. Trends Cancer. 2017;3(1):56\u201371.","journal-title":"Trends Cancer"},{"key":"2763_CR14","doi-asserted-by":"crossref","unstructured":"Liu M, Huang Q, A J, Li L, Li X, Zhang Z, et al. The cardiac glycoside deslanoside exerts anticancer activity in prostate cancer cells by modulating multiple signaling pathways. Cancers (Basel) 2021;13(22):5809.","DOI":"10.3390\/cancers13225809"},{"issue":"3","key":"2763_CR15","doi-asserted-by":"publisher","first-page":"e90353","DOI":"10.1371\/journal.pone.0090353","volume":"9","author":"JC Morris","year":"2014","unstructured":"Morris JC, Tan AR, Olencki TE, Shapiro GI, Dezube BJ, Reiss M, et al. Phase I study of GC1008 (fresolimumab): a human anti-transforming growth factor-beta (TGF\u03b2) monoclonal antibody in patients with advanced malignant melanoma or renal cell carcinoma. PLoS One. 2014;9(3):e90353.","journal-title":"PLoS One"},{"issue":"6","key":"2763_CR16","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1177\/0192623311416259","volume":"39","author":"MJ Anderton","year":"2011","unstructured":"Anderton MJ, Mellor HR, Bell A, Sadler C, Pass M, Powell S, et al. Induction of heart valve lesions by small-molecule ALK5 inhibitors. Toxicol Pathol. 2011;39(6):916\u201324.","journal-title":"Toxicol Pathol"},{"issue":"27","key":"2763_CR17","doi-asserted-by":"publisher","first-page":"18184","DOI":"10.1074\/jbc.M109.007096","volume":"284","author":"P Guo","year":"2009","unstructured":"Guo P, Zhao KW, Dong XY, Sun X, Dong JT. Acetylation of KLF5 alters the assembly of p15 transcription factors in transforming growth factor-beta-mediated induction in epithelial cells. J Biol Chem. 2009;284(27):18184\u201393.","journal-title":"J Biol Chem"},{"issue":"10","key":"2763_CR18","doi-asserted-by":"publisher","first-page":"6071","DOI":"10.1074\/jbc.M806270200","volume":"284","author":"P Guo","year":"2009","unstructured":"Guo P, Dong XY, Zhang X, Zhao KW, Sun X, Li Q, et al. Pro-proliferative factor KLF5 becomes anti-proliferative in epithelial homeostasis upon signaling-mediated modification. J Biol Chem. 2009;284(10):6071\u20138.","journal-title":"J Biol Chem"},{"issue":"24","key":"2763_CR19","doi-asserted-by":"publisher","first-page":"4919","DOI":"10.1128\/MCB.00787-13","volume":"33","author":"B Zhang","year":"2013","unstructured":"Zhang B, Zhang Z, Xia S, Xing C, Ci X, Li X, et al. KLF5 activates microRNA 200 transcription to maintain epithelial characteristics and prevent induced epithelial-mesenchymal transition in epithelial cells. Mol Cell Biol. 2013;33(24):4919\u201335.","journal-title":"Mol Cell Biol"},{"issue":"3","key":"2763_CR20","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1002\/ijc.22696","volume":"136","author":"X Li","year":"2015","unstructured":"Li X, Zhang B, Wu Q, Ci X, Zhao R, Zhang Z, et al. Interruption of KLF5 acetylation converts its function from tumor suppressor to tumor promoter in prostate cancer cells. Int J Cancer. 2015;136(3):536\u201346.","journal-title":"Int J Cancer"},{"issue":"1","key":"2763_CR21","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1038\/s41467-020-14737-8","volume":"11","author":"B Zhang","year":"2020","unstructured":"Zhang B, Ci X, Tao R, Ni JJ, Xuan X, King JL, et al. Klf5 acetylation regulates luminal differentiation of basal progenitors in prostate development and regeneration. Nat Commun. 2020;11(1):997.","journal-title":"Nat Commun"},{"issue":"17","key":"2763_CR22","doi-asserted-by":"publisher","first-page":"7656","DOI":"10.7150\/thno.44567","volume":"10","author":"Y Li","year":"2020","unstructured":"Li Y, Zhang B, Xiang L, Xia S, Kucuk O, Deng X, et al. TGF-\u03b2 causes docetaxel resistance in prostate cancer via the induction of Bcl-2 by acetylated KLF5 and protein stabilization. Theranostics. 2020;10(17):7656\u201370.","journal-title":"Theranostics"},{"issue":"1","key":"2763_CR23","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1038\/s41467-021-21976-w","volume":"12","author":"B Zhang","year":"2021","unstructured":"Zhang B, Li Y, Wu Q, Xie L, Barwick B, Fu C, et al. Acetylation of KLF5 maintains EMT and tumorigenicity to cause chemoresistant bone metastasis in prostate cancer. Nat Commun. 2021;12(1):1714.","journal-title":"Nat Commun"},{"issue":"5","key":"2763_CR24","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1177\/2472555217689884","volume":"22","author":"S Cribbes","year":"2017","unstructured":"Cribbes S, Kessel S, McMenemy S, Qiu J, Chan LL. A novel multiparametric drug-scoring method for high-throughput screening of 3D multicellular tumor spheroids using the celigo image cytometer. SLAS Discov. 2017;22(5):547\u201357.","journal-title":"SLAS Discov"},{"key":"2763_CR25","doi-asserted-by":"crossref","unstructured":"Berens EB, Holy JM, Riegel AT, Wellstein A. A cancer cell spheroid assay to assess invasion in a 3D setting. J Vis Exp. 2015;(105):53409.","DOI":"10.3791\/53409-v"},{"issue":"1","key":"2763_CR26","doi-asserted-by":"publisher","first-page":"2981","DOI":"10.1038\/s41467-018-05366-3","volume":"9","author":"T Kuchimaru","year":"2018","unstructured":"Kuchimaru T, Kataoka N, Nakagawa K, Isozaki T, Miyabara H, Minegishi M, et al. A reliable murine model of bone metastasis by injecting cancer cells through caudal arteries. Nat Commun. 2018;9(1):2981.","journal-title":"Nat Commun"},{"issue":"4","key":"2763_CR27","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1038\/nmeth.1923","volume":"9","author":"B Langmead","year":"2012","unstructured":"Langmead B, Salzberg SL. Fast gapped-read alignment with Bowtie 2. Nat Methods. 2012;9(4):357\u20139.","journal-title":"Nat Methods"},{"issue":"23","key":"2763_CR28","doi-asserted-by":"publisher","first-page":"11428","DOI":"10.1073\/pnas.1902651116","volume":"116","author":"W Abida","year":"2019","unstructured":"Abida W, Cyrta J, Heller G, Prandi D, Armenia J, Coleman I, et al. Genomic correlates of clinical outcome in advanced prostate cancer. Proc Natl Acad Sci U S A. 2019;116(23):11428\u201336.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"2763_CR29","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.ccr.2010.05.026","volume":"18","author":"BS Taylor","year":"2010","unstructured":"Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver BS, et al. Integrative genomic profiling of human prostate cancer. Cancer Cell. 2010;18(1):11\u201322 NCBI Gene Expression Omnibus (GEO) https:\/\/identifiers.org\/geo: GSE21034.","journal-title":"Cancer Cell"},{"key":"2763_CR30","doi-asserted-by":"crossref","unstructured":"Li J, Zhang B, Liu M, Fu X, Ci X, A J, et al. KLF5 is crucial for androgen-AR signaling to transactivate genes and promote cell proliferation in prostate cancer cells. Cancers (Basel) 2020;12(3):748.","DOI":"10.3390\/cancers12030748"},{"issue":"3","key":"2763_CR31","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1097\/SLA.0000000000001874","volume":"264","author":"CJ D\u00edaz-D\u00edaz","year":"2016","unstructured":"D\u00edaz-D\u00edaz CJ, Ronnekleiv-Kelly SM, Nukaya M, Geiger PG, Balbo S, Dator R, et al. The aryl hydrocarbon receptor is a repressor of inflammation-associated colorectal tumorigenesis in mouse. Ann Surg. 2016;264(3):429\u201336.","journal-title":"Ann Surg"},{"issue":"6","key":"2763_CR32","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/j.urolonc.2018.03.009","volume":"36","author":"ER Pego","year":"2018","unstructured":"Pego ER, Fern\u00e1ndez I, N\u00fa\u00f1ez MJ. Molecular basis of the effect of MMP-9 on the prostate bone metastasis: a review. Urol Oncol. 2018;36(6):272\u201382.","journal-title":"Urol Oncol"},{"key":"2763_CR33","doi-asserted-by":"crossref","unstructured":"Zhu L, Tang Y, Li XY, Keller ET, Yang J, Cho JS, et al. Osteoclast-mediated bone resorption is controlled by a compensatory network of secreted and membrane-tethered metalloproteinases. Sci Transl Med. 2020;12(529).","DOI":"10.1126\/scitranslmed.aaw6143"},{"issue":"12","key":"2763_CR34","doi-asserted-by":"publisher","first-page":"5794","DOI":"10.7150\/thno.56604","volume":"11","author":"Q Li","year":"2021","unstructured":"Li Q, Wang M, Hu Y, Zhao E, Li J, Ren L, et al. MYBL2 disrupts the Hippo-YAP pathway and confers castration resistance and metastatic potential in prostate cancer. Theranostics. 2021;11(12):5794\u2013812.","journal-title":"Theranostics"},{"issue":"6","key":"2763_CR35","doi-asserted-by":"publisher","first-page":"2876","DOI":"10.1038\/nprot.2006.202","volume":"1","author":"NJ Greenfield","year":"2006","unstructured":"Greenfield NJ. Using circular dichroism spectra to estimate protein secondary structure. Nat Protoc. 2006;1(6):2876\u201390.","journal-title":"Nat Protoc"},{"issue":"1","key":"2763_CR36","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1042\/BJ20130418","volume":"456","author":"XR Lv","year":"2013","unstructured":"Lv XR, Zheng B, Li SY, Han AL, Wang C, Shi JH, et al. Synthetic retinoid Am80 up-regulates apelin expression by promoting interaction of RAR\u03b1 with KLF5 and Sp1 in vascular smooth muscle cells. Biochem J. 2013;456(1):35\u201346.","journal-title":"Biochem J"},{"key":"2763_CR37","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.antiviral.2014.07.014","volume":"110","author":"JF Rossignol","year":"2014","unstructured":"Rossignol JF. Nitazoxanide: a first-in-class broad-spectrum antiviral agent. Antiviral Res. 2014;110:94\u2013103.","journal-title":"Antiviral Res"},{"issue":"1","key":"2763_CR38","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1586\/14787210.2.1.43","volume":"2","author":"CA White Jr","year":"2004","unstructured":"White CA Jr. Nitazoxanide: a new broad spectrum antiparasitic agent. Expert Rev Anti Infect Ther. 2004;2(1):43\u20139.","journal-title":"Expert Rev Anti Infect Ther"},{"issue":"8","key":"2763_CR39","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1038\/s41571-021-00499-9","volume":"18","author":"LC Hofbauer","year":"2021","unstructured":"Hofbauer LC, Bozec A, Rauner M, Jakob F, Perner S, Pantel K. Novel approaches to target the microenvironment of bone metastasis. Nat Rev Clin Oncol. 2021;18(8):488\u2013505.","journal-title":"Nat Rev Clin Oncol"},{"issue":"2","key":"2763_CR40","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.trecan.2020.09.006","volume":"7","author":"G Furesi","year":"2021","unstructured":"Furesi G, Rauner M, Hofbauer LC. Emerging players in prostate cancer-bone niche communication. Trends Cancer. 2021;7(2):112\u201321.","journal-title":"Trends Cancer"},{"issue":"4","key":"2763_CR41","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1002\/jcb.10662","volume":"91","author":"ET Keller","year":"2004","unstructured":"Keller ET, Brown J. Prostate cancer bone metastases promote both osteolytic and osteoblastic activity. J Cell Biochem. 2004;91(4):718\u201329.","journal-title":"J Cell Biochem"},{"issue":"3","key":"2763_CR42","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1002\/pros.1065","volume":"47","author":"DL Lin","year":"2001","unstructured":"Lin DL, Tarnowski CP, Zhang J, Dai J, Rohn E, Patel AH, et al. Bone metastatic LNCaP-derivative C4-2B prostate cancer cell line mineralizes in vitro. Prostate. 2001;47(3):212\u201321.","journal-title":"Prostate"},{"key":"2763_CR43","doi-asserted-by":"publisher","first-page":"781640","DOI":"10.3389\/fphar.2021.781640","volume":"12","author":"CH Li","year":"2021","unstructured":"Li CH, L\u00fc ZR, Zhao ZD, Wang XY, Leng HJ, Niu Y, et al. Nitazoxanide, an antiprotozoal drug, reduces bone loss in ovariectomized mice by inhibition of RANKL-induced osteoclastogenesis. Front Pharmacol. 2021;12:781640.","journal-title":"Front Pharmacol"},{"issue":"6","key":"2763_CR44","doi-asserted-by":"publisher","first-page":"e2895","DOI":"10.1038\/cddis.2017.244","volume":"8","author":"J Musa","year":"2017","unstructured":"Musa J, Aynaud MM, Mirabeau O, Delattre O, Gr\u00fcnewald TG. MYBL2 (B-Myb): a central regulator of cell proliferation, cell survival and differentiation involved in tumorigenesis. Cell Death Dis. 2017;8(6):e2895.","journal-title":"Cell Death Dis."},{"issue":"Pt B","key":"2763_CR45","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.addr.2015.11.017","volume":"99","author":"M Futakuchi","year":"2016","unstructured":"Futakuchi M, Fukamachi K, Suzui M. Heterogeneity of tumor cells in the bone microenvironment: Mechanisms and therapeutic targets for bone metastasis of prostate or breast cancer. Adv Drug Deliv Rev. 2016;99(Pt B):206\u201311.","journal-title":"Adv Drug Deliv Rev"},{"issue":"17","key":"2763_CR46","doi-asserted-by":"publisher","first-page":"5606","DOI":"10.1158\/0008-5472.CAN-11-1194","volume":"71","author":"D Javelaud","year":"2011","unstructured":"Javelaud D, Alexaki VI, Dennler S, Mohammad KS, Guise TA, Mauviel A. TGF-beta\/SMAD\/GLI2 signaling axis in cancer progression and metastasis. Cancer Res. 2011;71(17):5606\u201310.","journal-title":"Cancer Res"},{"issue":"11","key":"2763_CR47","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1038\/nm.3961","volume":"21","author":"DL Waning","year":"2015","unstructured":"Waning DL, Mohammad KS, Reiken S, Xie W, Andersson DC, John S, et al. Excess TGF-beta mediates muscle weakness associated with bone metastases in mice. Nat Med. 2015;21(11):1262\u201371.","journal-title":"Nat Med"},{"issue":"41","key":"2763_CR48","doi-asserted-by":"publisher","first-page":"28243","DOI":"10.1074\/jbc.M109.036160","volume":"284","author":"P Guo","year":"2009","unstructured":"Guo P, Dong XY, Zhao K, Sun X, Li Q, Dong JT. Opposing effects of KLF5 on the transcription of MYC in epithelial proliferation in the context of transforming growth factor beta. J Biol Chem. 2009;284(41):28243\u201352.","journal-title":"J Biol Chem"},{"issue":"2","key":"2763_CR49","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1002\/hed.26932","volume":"44","author":"T Liu","year":"2022","unstructured":"Liu T, Dai S, Zhang H, Zhong X, Ding Z, Ma X. The best choice of induction chemotherapy for patients with locally advanced nasopharyngeal carcinoma: Bayesian network meta-analysis. Head Neck. 2022;44(2):518\u201329.","journal-title":"Head Neck"},{"key":"2763_CR50","doi-asserted-by":"crossref","unstructured":"Yurttas C, Hoffmann G, Tolios A, Haen SP, Schwab M, K\u00f6nigsrainer I, et al. Systematic review of variations in hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal metastasis from colorectal cancer. J Clin Med. 2018;7(12):567.","DOI":"10.3390\/jcm7120567"},{"key":"2763_CR51","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.mrfmmm.2014.05.005","volume":"768","author":"N Di Santo","year":"2014","unstructured":"Di Santo N, Ehrisman J. A functional perspective of nitazoxanide as a potential anticancer drug. Mutat Res. 2014;768:16\u201321.","journal-title":"Mutat Res"},{"key":"2763_CR52","doi-asserted-by":"crossref","unstructured":"Abd El-Fadeal NM, Nafie MS, M KE-K, El-Mistekawy A, HMF M, Elbahaie AM, et al. Antitumor activity of nitazoxanide against colon cancers: molecular docking and experimental studies based on wnt\/\u03b2-catenin signaling inhibition. Int J Mol Sci. 2021;22(10):5213.","DOI":"10.3390\/ijms22105213"},{"issue":"11","key":"2763_CR53","doi-asserted-by":"publisher","first-page":"2345","DOI":"10.1038\/s41388-019-1142-6","volume":"39","author":"P Ripani","year":"2020","unstructured":"Ripani P, Delp J, Bode K, Delgado ME, Dietrich L, Betzler VM, et al. Thiazolides promote G1 cell cycle arrest in colorectal cancer cells by targeting the mitochondrial respiratory chain. Oncogene. 2020;39(11):2345\u201357.","journal-title":"Oncogene"},{"issue":"3","key":"2763_CR54","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.3390\/cancers5031163","volume":"5","author":"N Di Santo","year":"2013","unstructured":"Di Santo N, Ehrisman J. Research perspective: potential role of nitazoxanide in ovarian cancer treatment. Old drug, new purpose? Cancers (Basel). 2013;5(3):1163\u201376.","journal-title":"Cancers (Basel)"},{"issue":"6","key":"2763_CR55","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1158\/1535-7163.MCT-14-0792","volume":"14","author":"W Senkowski","year":"2015","unstructured":"Senkowski W, Zhang X, Olofsson MH, Isacson R, H\u00f6glund U, Gustafsson M, et al. Three-dimensional cell culture-based screening identifies the anthelmintic drug nitazoxanide as a candidate for treatment of colorectal cancer. Mol Cancer Ther. 2015;14(6):1504\u201316.","journal-title":"Mol Cancer Ther"},{"issue":"1","key":"2763_CR56","doi-asserted-by":"publisher","first-page":"8943","DOI":"10.1038\/s41598-022-12519-4","volume":"12","author":"F Ek","year":"2022","unstructured":"Ek F, Blom K, Selvin T, Rudfeldt J, Andersson C, Senkowski W, et al. Sorafenib and nitazoxanide disrupt mitochondrial function and inhibit regrowth capacity in three-dimensional models of hepatocellular and colorectal carcinoma. Sci Rep. 2022;12(1):8943.","journal-title":"Sci Rep"},{"key":"2763_CR57","doi-asserted-by":"publisher","first-page":"895573","DOI":"10.3389\/fphar.2022.895573","volume":"13","author":"S Huang","year":"2022","unstructured":"Huang S, Xiao J, Wu J, Liu J, Feng X, Yang C, et al. Tizoxanide promotes apoptosis in glioblastoma by inhibiting CDK1 activity. Front Pharmacol. 2022;13:895573.","journal-title":"Front Pharmacol"},{"issue":"10","key":"2763_CR58","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1038\/s41419-018-1058-z","volume":"9","author":"X Wang","year":"2018","unstructured":"Wang X, Shen C, Liu Z, Peng F, Chen X, Yang G, et al. Nitazoxanide, an antiprotozoal drug, inhibits late-stage autophagy and promotes ING1-induced cell cycle arrest in glioblastoma. Cell Death Dis. 2018;9(10):1032.","journal-title":"Cell Death Dis"},{"issue":"8","key":"2763_CR59","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1007\/s13205-020-02332-z","volume":"10","author":"AK Pal","year":"2020","unstructured":"Pal AK, Nandave M, Kaithwas G. Chemoprophylactic activity of nitazoxanide in experimental model of mammary gland carcinoma in rats. 3 Biotech. 2020;10(8):338.","journal-title":"3 Biotech"},{"issue":"9","key":"2763_CR60","doi-asserted-by":"publisher","first-page":"1896","DOI":"10.1158\/1535-7163.MCT-12-1243","volume":"12","author":"H Fan-Minogue","year":"2013","unstructured":"Fan-Minogue H, Bodapati S, Solow-Cordero D, Fan A, Paulmurugan R, Massoud TF, et al. A c-Myc activation sensor-based high-throughput drug screening identifies an antineoplastic effect of nitazoxanide. Mol Cancer Ther. 2013;12(9):1896\u2013905.","journal-title":"Mol Cancer Ther"},{"issue":"5","key":"2763_CR61","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1021\/acsmedchemlett.0c00544","volume":"12","author":"Z L\u00fc","year":"2021","unstructured":"L\u00fc Z, Li X, Li K, Wang C, Du T, Huang W, et al. Structure-activity study of nitazoxanide derivatives as novel STAT3 pathway inhibitors. ACS Med Chem Lett. 2021;12(5):696\u2013703.","journal-title":"ACS Med Chem Lett"},{"issue":"1","key":"2763_CR62","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1038\/nchembio.2510","volume":"14","author":"Y Qu","year":"2018","unstructured":"Qu Y, Olsen JR, Yuan X, Cheng PF, Levesque MP, Brokstad KA, et al. Small molecule promotes \u03b2-catenin citrullination and inhibits Wnt signaling in cancer. Nat Chem Biol. 2018;14(1):94\u2013101.","journal-title":"Nat Chem Biol"},{"key":"2763_CR63","doi-asserted-by":"publisher","first-page":"968148","DOI":"10.3389\/fphar.2022.968148","volume":"13","author":"SA Khan","year":"2022","unstructured":"Khan SA, Lee TKW. Investigations of nitazoxanide molecular targets and pathways for the treatment of hepatocellular carcinoma using network pharmacology and molecular docking. Front Pharmacol. 2022;13:968148.","journal-title":"Front Pharmacol"},{"key":"2763_CR64","doi-asserted-by":"publisher","first-page":"114913","DOI":"10.1016\/j.bcp.2022.114913","volume":"197","author":"Z L\u00fc","year":"2022","unstructured":"L\u00fc Z, Li X, Li K, Ripani P, Shi X, Xu F, et al. Nitazoxanide and related thiazolides induce cell death in cancer cells by targeting the 20S proteasome with novel binding modes. Biochem Pharmacol. 2022;197:114913.","journal-title":"Biochem Pharmacol"}],"container-title":["BMC Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-023-02763-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12916-023-02763-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-023-02763-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,21]],"date-time":"2023-02-21T15:08:45Z","timestamp":1676992125000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmedicine.biomedcentral.com\/articles\/10.1186\/s12916-023-02763-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,21]]},"references-count":64,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["2763"],"URL":"https:\/\/doi.org\/10.1186\/s12916-023-02763-4","relation":{},"ISSN":["1741-7015"],"issn-type":[{"value":"1741-7015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,21]]},"assertion":[{"value":"26 October 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 January 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 February 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All mice were maintained and handled following the National Institutes of Health guide for the Care and Use of Laboratory Animals. Animal experiments were performed with the approval of the Laboratory Animal Ethics Committee of Southern University of Science and Technology (Approval number: SUSTC-JY2019030-1).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"68"}}